---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-003304"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2025-03-19T23:59:59+00:00"
generated_at: "2026-05-24T11:29:46.004316+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Capricor Therapeutics reports Q4 net loss $7.1M, BLA for deramiocel accepted with PDUFA Aug 31, 2025

## Summary
- FDA accepted BLA for deramiocel to treat DMD cardiomyopathy; Priority Review, PDUFA date August 31, 2025.
- HOPE-2 OLE data showed 52% slowing of disease progression over 3 years vs external comparator (p=0.019).
- Cash balance $151.5M at Dec 31, 2024; received $10M milestone from Nippon Shinyaku in Jan 2025; cash runway into 2027.
- Q4 2024 revenue $11.1M (vs $12.1M Q4 2023); net loss $7.1M ($0.16/share) vs $0.8M loss ($0.02/share).
- Full year 2024 net loss $40.5M ($1.15/share) vs $22.3M ($0.83/share) in 2023; operating expenses $64.8M.

## SEC filing metadata
- accession: 0001558370-25-003304
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2025-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000155837025003304/0001558370-25-003304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000155837025003304/capr-20250319x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-003304
- JSON: https://secwatch.observer/filing/0001558370-25-003304.json
- Plain text: https://secwatch.observer/filing/0001558370-25-003304.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.